Skip to content
Menu

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga Insights 3 hours ago

Movers

Gainers InflaRx (NASDAQ:IFRX) stock rose 12.7% to $1.32 during Friday's after-market session. The market value of their outstanding shares is at $182.6 million. Instinct Bio Technical Co (NASDAQ:BIOT) stock moved

Gainers

  • InflaRx (NASDAQ:IFRX) stock rose 12.7% to $1.32 during Friday's after-market session. The market value of their outstanding shares is at $182.6 million.
  • Instinct Bio Technical Co (NASDAQ:BIOT) stock moved upwards by 5.83% to $0.2. The market value of their outstanding shares is at $5.4 million.
  • Can Fite Biopharma (AMEX:CANF) stock moved upwards by 4.34% to $1.48. The company's market cap stands at $3.1 million.
  • NextCure (NASDAQ:NXTC) stock moved upwards by 3.43% to $6.62. The market value of their outstanding shares is at $28.5 million. The company's, Q3 earnings came out 3 days ago.
  • Modular Medical (NASDAQ:MODD) stock rose 3.37% to $2.04. The market value of their outstanding shares is at $13.7 million.
  • Marker Therapeutics (NASDAQ:MRKR) shares increased by 2.88% to $0.9. The market value of their outstanding shares is at $15.0 million.

Losers

  • VolitionRX (AMEX:VNRX) shares declined by 6.3% to $0.22 during Friday's after-market session. The company's market cap stands at $5.5 million. The company's, Q3 earnings came out yesterday.
  • Xtant Medical Holdings (AMEX:XTNT) stock fell 5.34% to $0.27. The company's market cap stands at $38.6 million.
  • Akanda (NASDAQ:AKAN) shares declined by 5.0% to $1.3. The company's market cap stands at $1.7 million.
  • XORTX Therapeutics (NASDAQ:XRTX) shares decreased by 3.64% to $1.06. The company's market cap stands at $1.6 million.
  • NewGenIvf Group (NASDAQ:NIVF) stock fell 3.42% to $0.22.
  • Nautilus Biotechnology (NASDAQ:NAUT) stock fell 3.41% to $2.24. The company's market cap stands at $303.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Read the original